AN ENZYMATIC ASSAY TO MEASURE LONG-TERM ADHERENCE TO PRE EXPOSURE PROPHYLAXIS AND ANTIRETROVIRAL THERAPY
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
N/A
Issued Date -
N/A
app pub date -
Jun 12, 2020
filing date -
Jun 12, 2020
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The disclosure addresses methods, compositions, and kits used to detect or quantify polymerase inhibitors in biological samples. The polymerase inhibitors can be therapeutic agents, or metabolites thereof, that have been administered to a subject as part of, for example, antiretroviral therapy (ART) or pre-exposure prophylaxis (PrEP) to address potential infections by, e.g., retroviruses such as HIV and other viruses reliant on reverse transcription. These methods, compositions, and kits can be applied to monitor a subject's compliance with the indicated therapies and can inform potential adjustments to the therapies.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully